Additional European Equity News - 24th August 2026

Allreal (ALLN SW) - H1 (CHF): Net Income 75.6mln (prev. 62.6mln Y/Y). Confirms outlook. (Allreal) Bayer (BAYN GY) - Sevabertinib has received approval within Japan for those with Her-2 Mutant non-Small Cell Lung Cancer. (Bayer) Evolution (EVO SS) - Co. has acquired a total of 895,687 own shares within the framework of the repurchase program. (Evolution) GSK (GSK LN) - FDA accepts priority review for Jemperli in dMMR/MSI-H locally advanced rectal cancer; PDUFA date is Feb 2027. Seperately, Japan approves Hibsago for chronic hepatitis B, marking its first global approval. (GSK) Metso (METSO FH) - Co. enhances its slurry pumps portfolio with acquisition of hose and progressive cavity pumps business. (Metso) UK Insurance - The FT, citing sources, reports that Saudi Arabia has held talks with London brokers, for a potential state-backed scheme which could provide risk insurance/cover for ships in the region. (FT)